In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database

AIM: Describe the clinical and economic burden of hospitalizations for amyloid light chain (AL) amyloidosis. MATERIALS & METHODS: This retrospective analysis used nationally representative hospital discharge data (2017–2020) to report discharge status, resource use and costs for hospitalizations...

Descripción completa

Detalles Bibliográficos
Autores principales: Quock, Tiffany P, D'Souza, Anita, Broder, Michael S, Bognar, Katalin, Chang, Eunice, Tarbox, Marian H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288963/
https://www.ncbi.nlm.nih.gov/pubmed/36476016
http://dx.doi.org/10.2217/cer-2022-0185
Descripción
Sumario:AIM: Describe the clinical and economic burden of hospitalizations for amyloid light chain (AL) amyloidosis. MATERIALS & METHODS: This retrospective analysis used nationally representative hospital discharge data (2017–2020) to report discharge status, resource use and costs for hospitalizations among patients with AL amyloidosis. RESULTS: Of 1341 patients identified, 92% were discharged alive and 8% experienced in-hospital death. Compared with the average US hospital stay during 2017–2019 (4.7 days, mean costs of $13,046 and mean charges of $54,496), hospital stays for AL amyloidosis were longer and costlier (9.7 days, $27,098.61, $111,233.91), especially in patients with in-hospital death (12.2 days, $44,966, $182,338.18). CONCLUSION: AL amyloidosis is associated with significant clinical and economic burden.

Ejemplares similares